tiprankstipranks
Trending News
More News >

Thiogenesis Advances Pediatric MASH Trial and Secures EU Patent

Story Highlights
Thiogenesis Advances Pediatric MASH Trial and Secures EU Patent

Don’t Miss TipRanks’ Half-Year Sale

Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has shared an update.

Thiogenesis Therapeutics Corp has received scientific advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use, supporting its submission of an Investigational Medicinal Product Dossier for a Phase 2a clinical trial targeting pediatric metabolic dysfunction-associated steatohepatitis (MASH). This trial will explore the safety and efficacy of TTI-0102, a prodrug of cysteamine, in children with MASH. Additionally, the company has been granted a European Union patent for its asymmetric disulfide prodrugs of cysteamine, enhancing its competitive position in the mitochondrial and metabolic disease sectors until 2038. These developments mark significant progress in Thiogenesis’s strategy to address serious pediatric conditions linked to mitochondrial dysfunction.

More about Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, California. It focuses on developing next-generation thiol-based therapies for mitochondrial diseases and pediatric metabolic conditions. The company is publicly traded on the TSX Venture Exchange and the OTCQX in the U.S.

Average Trading Volume: 30,131

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$34.73M

See more insights into TTI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1